Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.78 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.59 |
| ▸ | EGFR | P00533 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.49 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15854195 | 0.83 | ALDH1A1 (0.70) | KMT2AALDH1A1LMNAEGFRPOLB | |
| SCHEMBL17219664 | 0.83 | ALDH1A1 (0.70) | KMT2AALDH1A1LMNAEGFRPOLB | |
| SCHEMBL18219883 | 0.82 | KMT2A (0.69) | KMT2AALDH1A1LMNATDP1MAPT | |
| SCHEMBL20306892 | 0.80 | ALDH1A1 (0.67) | KMT2AALDH1A1LMNAEGFRPOLB | |
| SCHEMBL18219899 | 0.79 | KMT2A (0.65) | KMT2AALDH1A1LMNAEGFRMAPT | |
| SCHEMBL17120722 | 0.77 | KMT2A (0.62) | KMT2AALDH1A1LMNAEGFRMAPT | |
| SCHEMBL18219885 | 0.76 | KMT2A (0.70) | KMT2AALDH1A1LMNATDP1MAPT | |
| SCHEMBL25605819 | 0.76 | KMT2A (0.61) | KMT2AALDH1A1LMNATDP1EGFR | |
| SCHEMBL18219857 | 0.76 | KMT2A (0.60) | KMT2AALDH1A1LMNATDP1MAPT | |
| SCHEMBL17120743 | 0.76 | KMT2A (0.61) | KMT2AALDH1A1LMNAPOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220298213-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | VIVIDION THERAPEUTICS, INC. | 2022-09-22 | — | — | US | disclosed |
| US-20210002337-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | THE SCRIPPS RESEARCH INSTITUTE | 2021-01-07 | — | — | US | disclosed |
| US-10781239-B2 | In vivo engineered cereblon protein | VIVIDION THERAPEUTICS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200216507-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | VIVIDION THERAPEUTICS, INC. | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298213-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | CRBN, CDR2, DCUN1D4 | KMT2A 607/4885ALDH1A1 2798/4885LMNA 1798/4885 |
| US-20200216507-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | CRBN, CDR2, DCUN1D4 | KMT2A 607/4885ALDH1A1 2798/4885LMNA 1798/4885 |
| US-20210002337-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | CRBN, CDR2, DCUN1D4 | KMT2A 607/4885ALDH1A1 2798/4885LMNA 1798/4885 |
| US-10781239-B2 | In vivo engineered cereblon protein | CRBN, CDR2, DCUN1D4 | KMT2A 607/4885ALDH1A1 2798/4885LMNA 1798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.